155 related articles for article (PubMed ID: 28524099)
1. Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment.
Arias-Ramos N; Ferrer-Font L; Lope-Piedrafita S; Mocioiu V; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
Metabolites; 2017 May; 7(2):. PubMed ID: 28524099
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
[TBL] [Abstract][Full Text] [Related]
3. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
4. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Delgado-Goñi T; Ortega-Martorell S; Ciezka M; Olier I; Candiota AP; Julià-Sapé M; Fernández F; Pumarola M; Lisboa PJ; Arús C
NMR Biomed; 2016 Jun; 29(6):732-43. PubMed ID: 27061401
[TBL] [Abstract][Full Text] [Related]
5. Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Delgado-Goñi T; Julià-Sapé M; Candiota AP; Pumarola M; Arús C
NMR Biomed; 2014 Nov; 27(11):1333-45. PubMed ID: 25208348
[TBL] [Abstract][Full Text] [Related]
6. Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses.
Calero-Pérez P; Wu S; Arús C; Candiota AP
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071393
[TBL] [Abstract][Full Text] [Related]
7. Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma.
Massey SC; White H; Whitmire P; Doyle T; Johnston SK; Singleton KW; Jackson PR; Hawkins-Daarud A; Bendok BR; Porter AB; Vora S; Sarkaria JN; Hu LS; Mrugala MM; Swanson KR
PLoS One; 2020; 15(3):e0230492. PubMed ID: 32218600
[TBL] [Abstract][Full Text] [Related]
8. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
9. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
10. Tracking Therapy Response in Glioblastoma Using 1D Convolutional Neural Networks.
Ortega-Martorell S; Olier I; Hernandez O; Restrepo-Galvis PD; Bellfield RAA; Candiota AP
Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568818
[TBL] [Abstract][Full Text] [Related]
11. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I; Saiz-Ladera C; Torres S; Hernández-Tiedra S; García-Taboada E; Rodríguez-Fornés F; Barba M; Dávila D; Salvador-Tormo N; Guzmán M; Sepúlveda JM; Sánchez-Gómez P; Lorente M; Velasco G
Biochem Pharmacol; 2018 Nov; 157():266-274. PubMed ID: 30195736
[TBL] [Abstract][Full Text] [Related]
12. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice.
Ferrer-Font L; Villamañan L; Arias-Ramos N; Vilardell J; Plana M; Ruzzene M; Pinna LA; Itarte E; Arús C; Candiota AP
Pharmaceuticals (Basel); 2017 Feb; 10(1):. PubMed ID: 28208677
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
15. Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives.
Candiota AP; Arús C
Metabolites; 2022 Mar; 12(3):. PubMed ID: 35323686
[TBL] [Abstract][Full Text] [Related]
16. Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.
Li Q; Chen B; Cai J; Sun Y; Wang G; Li Y; Li R; Feng Y; Han B; Li J; Tian Y; Yi L; Jiang C
PLoS One; 2016; 11(3):e0151815. PubMed ID: 27022952
[TBL] [Abstract][Full Text] [Related]
17. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.
St-Coeur PD; Poitras JJ; Cuperlovic-Culf M; Touaibia M; Morin P
J Neurooncol; 2015 Oct; 125(1):91-102. PubMed ID: 26311249
[TBL] [Abstract][Full Text] [Related]
18. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
19. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
20. Image-fusion of MR spectroscopic images for treatment planning of gliomas.
Chang J; Thakur S; Perera G; Kowalski A; Huang W; Karimi S; Hunt M; Koutcher J; Fuks Z; Amols H; Narayana A
Med Phys; 2006 Jan; 33(1):32-40. PubMed ID: 16485406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
